INTRODUCTION
Long-chain polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA ; C #! : %,n−' ) and docosahexaenoic acid (DHA ; C ## : ',n−$ ), are important for neonatal growth and brain development [1, 2] . AA, an nk6 fatty acid, is a constituent of membrane phospholipids involved in signal transduction, and can be utilized for eicosanoid synthesis [3] . DHA, an nk3 fatty acid, is the main component of the PUFAs in retina and brain [4] . It has been shown that DHA intake is associated with increased visual acuity in infants, whereas DHA deficiency is associated with cognitive decline and the onset of Alzheimer's disease in adults [5] .
The nk6 and nk3 long-chain PUFAs are either obtained directly from the diet or derived from metabolism of dietary linoleic acid (LA ; C ") : $,n−' ) and α-linolenic acid (ALA ; C ") : $,n−$ ). In animal tissues, ∆'-desaturase converts LA into γ-linolenic acid (GLA ; C ") : $,n−' ), to which an elongase system adds two carbon atoms to synthesize dihomo-γ-linolenic acid (DGLA ; C #! : $,n−' ) (Scheme 1). In the nk3 pathway, ∆'-desaturase converts ALA into stearidonic acid (STA ; C ") : %,n−$ ), to which an elongase system adds two carbons to synthesize eicosatetraenoic acid (ETA ; C #! : %,n−$ ). A ∆&-desaturase converts DGLA and ETA into
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The predicted amino acid sequence of the open reading frame had only 29 % identity with the yeast ELO2 sequence, contained a single histidine-rich domain and had six transmembranespanning regions, as suggested by hydropathy analysis. The tissue expression profile revealed that the HELO1 gene is highly expressed in the adrenal gland and testis. Furthermore, the HELO1 gene is located on chromosome 6, best known for encoding the major histocompatibility complex, which is essential to the human immune response.
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AA and eicosapentaenoic acid (EPA ; C #! : &,n−$ ) respectively. Further elongation of EPA by two carbons results in the synthesis of ω3-docosapentaenoic acid (DPA ; C ## : &,n−$ ). It has generally been agreed that DHA is synthesized through conversion of DPA by a ∆%-desaturase. However, recent studies indicate that DHA can also be produced through an alternative pathway involving two elongation steps, from EPA to DPA and from DPA to ω3-tetracosapentaenoic acid (TPA ; C #% : &,n−$ ). This is followed by a ∆'-desaturation [TPA to ω3-tetracosahexaenoic acid (THA ; C #% : ',n−$ )], and retroconversion from THA into DHA by β-oxidation in the peroxisomes [6] . Similarly, in the nk6 pathway, AA can be elongated to adrenic acid (ADA ; C ## : %,n−' ), and ADA to ω6-tetracosatetraenoic acid (TTA ; C #% : %,n−' ). The TTA is ∆'-desaturated to ω6-tetracosapentaenoic acid (ω6-TPA ; C #% : &,n−' ), and ω6-TPA is then retroconverted into ω6-docosapentaenoic acid (ω6-DPA ; C ## : &,n−' ) [6] . Overall, formation of nk6 and nk3 long-chain PUFAs from their precursors LA and ALA requires at least three elongation steps and three or more different desaturases capable of utilizing long-chain PUFAs as substrates.
The fatty acid chain elongation system (FACES) in animals is a four-enzyme system consisting of condensing enzyme, β-oxoacyl-CoA reductase, β-hydroxyacyl-CoA dehydrase and
Scheme 1 Metabolic pathways of long-chain PUFAs
The common pathway for the synthesis of nk6 and nk3 C 22 fatty acids are shown with bold arrows, alternative pathways are shown with grey arrows, and retroconversion is shown with broken arrows.
trans-2-enoyl-CoA reductase [7] . Although FACES has been found in many tissues, the many forms of FACES, i.e. multiple condensing enzymes connected to a single pathway or to multiple pathways, are still unknown [8] . An animal fatty acid synthase has been characterized for shorter-chain-length saturated fatty acids [9] . More recently, very-long-chain (22j carbon atoms) acyl-coA synthetase from human liver was described to play a role in elongation of saturated very-longchain fatty acids or complex-lipid synthesis [10] . Although chainlength-specific PUFA-elongating enzymes were suggested to exist in rat microsomes [11] , no enzyme or enzyme systems responsible for the elongation of long-chain PUFAs have been identified from animals.
The yeast ELO1 gene, the product of which is involved in the elongation of C "% : ! to C "' : ! , was first identified in 1996 [12] . The ELO2 and ELO3 genes were identified later, based on identity with the ELO1 gene [13] . ELO2 protein is involved in the elongation of saturated and monounsaturated fatty acids up to 24 carbons in length, while ELO3 protein has a preference for a broader group of saturated and monounsaturated fatty acids, and is essential for the conversion of C
. All three proteins contain at least five membrane-spanning regions and a single histidine-box motif [13] . However, each of these three genes is thought to encode a single enzyme component of one or more systems that elongate saturated and monounsaturated, fatty acids, but not PUFAs.
Despite the identification of genes involved in the elongation of saturated and monounsaturated fatty acids from many organisms, no gene specific for elongation of long-chain PUFAs has been identified. In this paper we describe the isolation of a cDNA sequence, HELO1, from a human liver cDNA pool and demonstrate the ability of the encoded enzyme, HELO1p, to produce elongated long-chain PUFAs when expressed in bakers' yeast. We also report the distribution of the HELO1 transcript in various human tissues.
MATERIALS AND METHODS

Identification and cloning of the HELO1 cDNA
The Saccharomyces cere isiae ELO2 DNA sequence was used as a query to search the LifeSeq2 database of Incyte Pharmaceuticals, Inc. (Palo Alto, CA, U.S.A.). The search revealed a cluster (groups of clones related to one another by sequence identity) of human EST (expressed sequence tag) sequences (LifeSeq2 Cluster ID number CC067284R1) which exhibited sequence identity with ELO2. The edited consensus sequence of the cluster was then imported into the Sequencher software program (Gene Codes Corporation) and assembled to create a sequence of 897 bases, designated HELO1.
Primers RO719 (5h-GGT TCT CCC ATG GAA CAT TTT GAT GCA TC-3h) and RO720 (5h-GGT TTC AAA GCT TTG ACT TCA ATC CTT CCG-3h) were designed based on the putative HELO1 sequence, and used to amplify human liver Marathon-Ready2 cDNA. The termini of the approx. 960 bp by PCR-amplified product were filled-in with T4 DNA polymerase (Boehringer Mannheim, Indianapolis, IN, U.S.A.). The DNA fragment was then cloned into the pCR2-blunt vector (Invitrogen, Carlsbad, CA, U.S.A.), and the resulting plasmid was designated pRAE-52. The HELO1 sequence was isolated from this plasmid by NcoI\HindIII digestion and ligated into the pYX242 (NcoI\HindIII) vector (Novagen, Madison, WI, U.S.A.) to form another plasmid, designated pRAE-58.
Expression of the human cDNA in bakers' yeast
The plasmid DNA, pRAE-58, was transformed into S. cere isiae 334 and the resulting clones were screened for elongase activity [14] . S. cere isiae 334 containing the pYX242 vector alone was used as the negative control. The cultures were grown for 44 h at 30 mC in selective media containing individual substrates. GLA was used as the substrate for the initial screening. Later, different substrates such as AA, STA, EPA and ALA were also used to determine the activity of the expressed cDNA.
Fatty acid analysis
The yeast cell pellets were harvested and total lipids were extracted. The fatty acid distribution (as percentage of total fatty acids) in recombinant yeast cells containing either pRAE-58 or pYX242, in the presence of various substrates, was analysed using the method described previously [14] . Percentage conversion was calculated as [product\(substratejproduct)]i100.
Distribution of HELO1 mRNA
In order to quantify the amount of HELO1 mRNA in different human tissues, Taqman2 Real Time QPCR (Quantitative PCR) methodology was used as previously described [15] . HELO1 sequences used for primer design were as follows : forward primer 818F, 5h-CCA TGG CTG CTG TGA ATG G-3h ; reverse primer 886R, 5h-GCT TCC TTG GCT TCA CAT TGT T-3h ; Taqman2 
RESULTS
Identification of a putative human protein sequence involved in the elongation of fatty acids
The S. cere isiae ELO2 translated sequence was used as a query to search the LifeSeq2 database for a putative human protein sequence involved in long-chain PUFA elongation. The first of the two resulting full-length sequences consisted of 897 bp, which encoded a protein of 299 amino acids. Hydropathy analysis using the TMpredict algorithm suggested that this putative human protein, HELO1p, contained six transmembrane regions (Figure 1 ). The initial membrane-scanning region is located 32 residues from the start codon. A histidine box, often present in membrane-bound enzymes [16] , was found between predicted transmembrane regions III and IV, at amino acid positions 143-147 of the putative polypeptide encoded by the open reading frame (Figure 1) .
The translated HELO1 sequence exhibited 29n1 % identity with the S. cere isiae ELO2 sequence ( Figure 2 ) and 27n7 % identity with S. cere isiae ELO3 [13] . No other known enzymes involved in the elongation of fatty acids, such as acyl-CoA synthetase [11] or fatty acid synthase [17] , were found to have any significant identity with the HELO1 sequence.
The second resulting full-length sequence consisted of 837 bp, which encoded 279 amino acids. This putative human protein, HELO2p, had 27n3 % and 27n7 % identity with S. cere isiae ELO2 and ELO3 respectively (results not shown).
Expression of the human cDNAs in yeast
To demonstrate the two-carbon elongation of a long-chain PUFA, the recombinant yeast strain 334(pRAE-58) was grown in minimal medium supplemented with 25 µM of a long-chain PUFA substrate, GLA. The results in Figure 3 show that the fatty acid profile of the yeast strain 334(pRAE-58) was significantly different from that of the control strain, 334(pYX242). In particular, a fatty acid with a retention time identical with that of DGLA in GC accumulated to a level of 7n29 % of total fatty acids in strain 334(pRAE-58). The ion fragmentation pattern of this fatty acid was found to be identical with that of an authentic DGLA standard by GC-MS (results not shown). This peak represented 78n3 % conversion of the substrate fatty acid GLA into DGLA. This finding clearly demonstrated that GLA was elongated by two carbon atoms, and that HELO1p was indeed involved in the elongation of this PUFA substrate.
The overexpression of the S. cere isiae ELO2 cDNA in bakers' yeast in the presence of GLA resulted in 3n8 % conversion into DGLA, which was not significant compared with the 3n7 % conversion in the control strain (results not shown). The expression of HELO2p in bakers' yeast in the presence of GLA resulted in 2n4 % conversion into DGLA, which was not significant compared with the 1 % conversion in the control strain (results not shown). Based on these results, it appears that neither S. cere isiae ELO2 nor human HELO2p are involved in the elongation of GLA.
The yeast cells expressing the recombinant HELO1 sequence, when compared with the control cells, also contained significantly elevated levels of C ") : ",n−( and C #! : ",n−( , and to a lesser extent of eicosenoic acid (EA ; C #! : ",n−* ) ( Figure 3 ). This finding suggested that the recombinant HELO1p might also be involved in the elongation of monounsaturated fatty acids of 16 or 18 carbons. To confirm this hypothesis, 25 µM exogenous oleic acid was added as a substrate to the recombinant yeast strain 334(pRAE-58). After incubation, the accumulation of EA to represent 2n25 % of total fatty acids demonstrated that the expressed HELO1 enzyme can also increase the elongation of monounsaturated fatty acids (Table 1) . However, the percentage conversion of oleic acid into EA by recombinant HELO1p was only 8n9 % ; this was significantly lower than the endogenous conversion of C "' : ",n−( (into C ") : ",n−( ) or C ") : ",n−( (into C #! : ",n−( ), which were 20n4 % and 58n1 % respectively.
To test for the elongation of other PUFA substrates in the presence of this enzyme, the recombinant yeast strain 334 (pRAE-58) was grown in minimal medium containing another nk6 fatty acid (AA) or an nk3 fatty acid (STA, EPA or ALA) at a concentration of 25 µM. The lipid profiles of these yeast cultures, when examined by GC and GC-MS, indicated that there was accumulation of ADA, ETA, DPA and ω3-eicosatrienoic acid
Figure 2 Comparison of the deduced amino acid sequences of HELO1 and yeast ELO2
Identical residues are shaded in dark grey, and similar residues are boxed. The histidine-box region is underlined. 
Figure 3 GC analysis of fatty acid methyl esters from the lipid fraction of yeast cells containing pRAE-58 or control plasmid
The results from the extracts of HELO1-expressing cells are denoted with jpRAE-58. 
Figure 4 Fatty acid analysis of yeast cells containing pRAE-58 and of control cells, when grown in the presence of various substrates
The cultures were grown in the presence of the indicated substrates. (ETrA ; C #! : $,n−$ ) respectively (Figure 4 ). The levels of these fatty acids represented 6n26 % (ADA), 10n06 % (ETA), 6n66 % (DPA), and 6n15 % (ETrA) of the total fatty acids in the strain containing the pRAE-58 sequence. This represented 42n7 %, 79n2 %, 71n7 % and 30n4 % conversion respectively of the substrate fatty acids into the product elongated by two carbon atoms. All results confirmed that the expression of HELO1 from human liver in yeast resulted in the elongation of various long-chain PUFAs in nk6 and nk3 fatty acid pathways.
HELO1 mRNA distribution in human tissues
QPCR analysis of HELO1 expression in 22 human tissues revealed that the highest levels of HELO1 mRNA were found in Figure 5 Tissue distribution of HELO1
The abundance of expressed HELO1 in various human tissues is shown. The absolute content of cDNA added to each reaction was normalized with a 28 S rRNA QPCR control.
the testis and adrenal gland ( Figure 5 ). Other significant amounts of this mRNA were found in brain, lung and prostate tissue, each of which had approximately the same level. In these tissues, copy numbers of this mRNA per 10 ng of cDNA were approx. 50 % of that found in testis and adrenal gland. The level of HELO1 mRNA was lowest in pancreas tissue (approx. 36-fold lower than that found in brain, lung and prostate).
DISCUSSION
In the present study, the initial search for an enzyme involved in elongation of long-chain PUFAs began by examining known saturated and monounsaturated FACES. The animal fatty acid synthase had been characterized for shorter-chain-length saturated fatty acids [9] , and a very-long-chain acyl-coA synthetase from human liver was described to play a role in elongation of saturated very-long-chain fatty acids [10] . Also, chain-lengthspecific PUFA-elongating enzymes were suggested to exist in rat microsomes [11] . However, no enzyme or enzyme systems responsible for the elongation of long-chain PUFAs had been identified from animals. The yeast ELO2 and ELO3 genes were identified based on greater than 70 % similarity to the ELO1 gene [13] . These three gene products are all involved in the elongation of fatty acids, but they have different substrate preferences. ELO1 protein is involved in the elongation of C "% : ! to C "' : ! , while ELO2 and ELO3 are involved in the elongation of very-long-chain saturated and monounsaturated fatty acids [13] . Yeast mutants defective in C "# : ! elongation (mutated ELO1 ) had unimpaired elongation of C "' : ! , indicating that yeast may contain different elongation systems and that other components of elongation are unaffected by this gene mutation [18] .
Our approach was to identify a gene whose product is involved in the elongation of long-chain PUFA substrates, unlike yeast ELO2, which could be expressed in yeast. The HELO1 cDNA sequence, encoding a protein involved in the biosynthesis of long-chain PUFAs, was identified based on the limited identity between the S. cere isiae ELO2 and human EST sequences. When the HELO1 cDNA was expressed in yeast cells, its protein product was involved in the conversion of a wide range of exogenously added long-chain PUFA substrates into their respective elongated products : GLA into DGLA, AA into ADA, STA into ETA, EPA into DPA and ALA into ETrA (Figure 4 ). This human enzyme was also involved in the elongation of endogenous monounsaturated fatty acids to their respective elongated products, and thus exhibited a broad range of substrate specificity. However, when S. cere isiae ELO2 and human HELO2 were expressed in yeast cells, neither was involved in significant conversion of GLA into DGLA.
The elongation of ALA to ETrA seems to follow an alternative pathway for the synthesis of ETA, bypassing the requirement for ∆'-desaturase. In the nk3 pathway, ETrA is converted into ETA by a ∆)-desaturase [19] (Scheme 1). Although LA was not tested as a substrate in our study, it is likely that the recombinant HELO1p can add two carbons to LA to produce ω6-eicosadienoic acid (EDA ; C #! : #,n−' ) in bakers' yeast. Albert et al. [20] have shown that EDA was used as a precursor of AA in the nk6 pathway in human testes. It is interesting that the ∆)-desaturation pathway was present in human testis [20] , glioma [21] and breast cancer cells [22] , but not in corresponding noncancerous breast cells [22] or in the brain [23] . The elongation of ALA to ETrA is the first step by which C #! fatty acids can be metabolized in tissues with little or no ∆'-desaturase activity [22] . Hence HELO1p may be essential in the biosynthesis of DGLA or C #! : %,n−$ in either pathway involving ∆)-desaturation. As shown in Scheme 1, an alternative fatty acid biosynthesis pathway for ADA or DPA involves elongase, ∆'-desaturase and retroconversion activities [6] . ADA and DPA were added exogenously to test whether they could be elongated in yeast cells expressing HELO1p. Although ADA and DPA were effectively taken into the cells and reached as much as 49n89 % and 56n17 % respectively of total lipid, no C #% product was detected in any of the experiments (results not shown). Therefore the recombinant form of this human enzyme is not involved in the elongation of C ## PUFAs. When the predicted amino acid sequence encoded by HELO1 was compared with those of other enzymes known to be involved in the elongation of fatty acids, the human enzyme showed 29n1 % identity with S. cere isiae ELO2 (Figure 2 ) and 27n7 % identity with S. cere isiae ELO3 [13] . Although all three enzymes appear to be essential for the elongation of fatty acids by two carbon atoms, the identity of the protein sequences between the two species is limited. It is interesting to note that a translated mouse EST sequence (GenBank2 accession no. AI787925) had 92n5 % identity in a 106-amino-acid overlap with the HELO1 translated sequence. This high percentage identity between these two species suggests that a homologue of human HELO1p is also present in the mouse. To date, the domain of the enzyme which is responsible for substrate specificity, i.e. the ability to distinguish among saturated, monounsaturated and polyunsaturated fatty acids, has not yet been determined.
The tissue distribution of the HELO1 transcript in 22 different human tissues revealed that the highest levels of mRNA were found in the testis and adrenal gland ( Figure 5 ). These results are consistent with the fact that both tissues contain very high levels of ADA, which is synthesized by elongation of AA [24, 25] .
HELO1 is located on chromosome 6p12, centromeric to the major histocompatibility complex, which spans approx. 4 Mb on the short arm of the chromosome (6p21.3) [26] . Chromosome 6 is also believed to encode genes involved in genetic diseases, including arthritis [27] , diabetes [28] , haemochromatosis [29] , schizophrenia [30] , juvenile myoclonus epilepsy [31] , multiple sclerosis [32] , anterior eye chamber anomalies [33] , Parkinson's disease [34] , psoriasis [35] , inflammatory bowel disease [36] , and others. It is interesting that the HELO1 gene is mapped to this region, since nk3 and nk6 fatty acids, as well as the ratio between the two groups of fatty acids, have been associated with eye disorders [37] , diabetes, inflammatory disorders, and many other diseases [38] . Further experiments are needed to study the regulation of HELO1 gene expression in various disease conditions.
In summary, we have identified two human genes that have limited identity with the yeast ELO2 and ELO3 genes. Expression of HELO1 cDNA in bakers' yeast produced an active enzyme that is involved in the elongation of PUFAs and monounsaturated fatty acids, while expression of HELO2 cDNA in bakers' yeast produced an enzyme that was not involved in the elongation of PUFA.
